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This article explores the views and experiences of healthcare professionals and clinical scientists in genetics about the existence
of a duty and/or responsibility to recontact former patients when the genetic information relevant to their health, or that of family
members, changes in a potentially important manner. It is based on N=30 semi-structured interviews guided by vignettes of
recontacting scenarios. The sample included healthcare professionals in the United Kingdom from different medical specialties
(clinical genetics, other ‘mainstream’ specialties now offering genetic testing), and scientists from regional genetics laboratories.
While viewing recontacting as desirable under certain circumstances, most respondents expressed concerns about its feasibility
within the current constraints of the National Health Service (NHS). The main barriers identiﬁed were insufﬁcient resources
(time, staff, and suitable IT infrastructures) and lack of clarity about role boundaries and responsibilities. All of these are further
complicated by genetic testing being increasingly offered by mainstream specialties. Reaching a consensus about roles and
responsibilities of clinical specialties with regard to recontacting former patients in the light of evolving genetic information, and
about what resources and infrastructures would be needed, was generally seen as a pre-requisite to developing guidelines about
recontact.
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INTRODUCTION
Advances in genomic medicine are producing new interpretations of
data that can lead to better diagnosis and treatment of some health
conditions. Novel research ﬁndings sometimes have implications for
previously reported diagnoses and test results. These implications
might also be at the level of treatment and surveillance options, such
as the identiﬁcation of PARP inhibitors as a possible treatment for
BRCA-related carriers. With the increasing use of whole genome
approaches in healthcare, previously discovered variants of unknown
signiﬁcance (VUSs) may now have known disease effects, or they may
be re-classiﬁed from pathogenic to non-pathogenic. Such reinterpreta-
tions are likely to become more common as clinical practice moves
away from targeted tests and towards genome-wide approaches, which
identify more variants of unknown or uncertain clinical signiﬁcance.
A recent reclassiﬁcation of BRCA1 c.594-2A4C from pathogenic1 has
triggered an alert from the UK’s Association for Clinical Genetics
Science to identify families and individuals who had tested positive for
this variant.
Is there a duty or responsibility on the part of clinicians to recontact
former patients for whom the interpretation of genetic test results has
changed in a clinically important way?
The literature on recontacting is sparse. A recent systematic review
by Otten et al.2 found that a common theme was the clash between
the desirability of recontacting and its practical feasibility. The main
practical barriers identiﬁed were lack of resources (eg, time, staff),
and infrastructures (eg, sufﬁcient patient databases).3,4 The main
suggestions to help mitigate these barriers were the implementation of
digital communication systems between laboratories, clinicians and
patients and the involvement of patients and support groups in the
process of recontacting – that is, to encourage patients routinely to
recontact healthcare professionals (HCPs) for updates.5,6
There is a lack of consistency and clarity around terminology. In the
literature, the expression ‘duty to recontact’ prevails, but ‘responsi-
bility’, ‘obligation’ and other terms are sometimes used as synonyms.
The systematic review adopts the term ‘duty’ and deﬁnes it as the
ethical and/or legal obligation to recontact former patients in light of
new genetic ﬁndings.2 We follow this deﬁnition but we also consider
there are important distinctions between ‘duty’ and ‘responsibility’.
There is currently no policy, legislation or professional consensus
about whether healthcare professionals have a duty to recontact
former patients. However, cases where legal liability has been
established shed some light on the potential duty to recontact.
USA and Canadian courts have established a duty to warn (which is
more general than the duty to recontact, and not necessarily directed
at a particular patient) in cases of defective drugs or devices.
A physician who prescribed treatments, drugs and other medical
devices may still have a duty to inform patients if new information
about additional risks related to these medical treatments becomes
available.7,8 In Tresner v Barke, a California case related to a
contraceptive device (Dalkon Shield), a physician who inserted this
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device has been held liable for not having communicated to patients a
later discovery about its side effects.9 Focusing completely on the legal
interpretation of duty may obscure the ethical complexities involved in
recontacting.10–12 For example, to date the courts have considered there
is no legal duty of care to relatives.13,14 However, HCPs may still have
an ethical duty to contact the relatives of a patient to alert them to
actionable risk, as reﬂected by the recent Australian guidelines which
approves direct communication between HCPs and relatives to disclose
at risk status in case of a serious threat even without the patient’s
consent (although the guidelines encourage clinicians to work hard to
gain patient consent for disclosure before contacting relatives).15
If there is a duty or responsibility to recontact former patients, the
next question is with whom would this lie. Genetic testing is beginning
to be offered by medical specialists outside clinical genetics, so-called
‘mainstream specialties’, for example, cardiology, paediatrics, and
oncology; yet these specialties may not receive up-to-date information
on DNA variant interpretation. Therefore, the most appropriate lines
of responsibility for recontacting could be unclear. Genetic HCPs may
be responsible for recontacting patients and families to whom they
offer on-going care.7 However, much on-going genetic care has
devolved to primary and/or secondary care, rather than by genetic
services.16 For some multisystem disorders, genetic services coordinate
care across specialties and this might facilitate appropriate recontact,
but coverage to date is uneven. Laboratory staff may learn about
reclassiﬁcations of VUSs before clinical staff and may be able to notify
clinicians,17 triggering a recontact.
Other questions include: how long a potential duty or responsibility
to recontact might apply, and what types and degrees of information
change might justify or trigger recontacting a former patient.18,19
These questions will become more urgent if health care systems move
towards the model of universal whole-genome sequencing with the
lifetime storage of each citizen’s genome sequence to be accessed as
required for health care decisions.20
There is very limited empirical evidence on recontacting. Our recent
survey was the ﬁrst study to speciﬁcally explore current recontacting
practices in regional clinical genetics services.21 This showed that
services in the UK do recontact former patients but in an ad hoc
fashion. More than half of the services were uncertain about whether
formalised recontacting systems were desirable. Some argued that
implementing such systems would give patients more choice and lead
to a better standard of care. Others expressed concerns that establish-
ing a duty to recontact may create a worrisome legal precedent that
would be difﬁcult to enact universally. In order to provide much
needed empirical evidence, this paper draws on interviews with
healthcare professionals from clinical genetics, professionals from
mainstream specialties, and scientists working in genetic service
laboratories. It provides an in-depth investigation of their perspectives
on the clinical, ethical and legal issues related to recontacting.
METHODS
The interviews we conducted are part of a broader study to investigate ethical,
legal and social issues related to recontacting in clinical practice in the NHS in
the United Kingdom (study website: http://ex.ac.uk.//mgc). The sample
comprised healthcare professionals and laboratory scientists (n= 30) recruited
via NHS trusts and professional societies (see Table 1). Participants were
identiﬁed and invited to participate by the clinical authors of this paper based
on their professional experience and networks. In this sense the sampling
strategy was purposive. A multi-site strategy was adopted to gain a sample of
participants from different medical specialties. Interviews were semi-structured
and face-to-face, except for one conducted via Skype. We investigated:
experiences of recontacting; views about situations in which recontact may/
may not be regarded as a good standard of care; and views about potential
responsibilities for recontacting and the implementation of policies and systems
to enable this. The interviews were guided by three vignettes (about new
diagnosis, reclassiﬁcation of a VUS, and new treatment for an old ﬁnding).
Vignettes are increasingly recognised as useful tools in interviews where the
objective is to query responses to variation in clinical practice or to situations
posing professional and/or ethical quandaries regarding action, and are useful
in obtaining ‘accounts’ of both action and reasoning.22 We designed the
vignettes based on the literature, clinical experience, and survey ﬁndings21 and
piloted them with the ﬁrst few participants.
Interviews were recorded, transcribed verbatim and subjected to thematic
analysis.23 The interviews were independently analysed by three members of the
research team. Key themes were identiﬁed and discussed in regular team
meetings. The interview guide and vignettes are provided as Supplementary
Information A and B.
RESULTS
Sample
The categories below refer to the respondents’ main role at the time of
the interview. However some of the respondents had more than one
clinical area of interest and varied clinical backgrounds. The HCPs and
laboratory staff interviewed were mostly very experienced and
occupied senior positions. To gain a mix of perspectives (in particular
from those who were more recently trained) a small number of less
senior HCPs (trainees doctors in medical genetics) was also recruited.
No standard recontacting practices
In line with the ﬁndings from our survey,21 the genetic HCPs reported
that they recontact patients occasionally. The most frequently men-
tioned cases were: the availability of new genetic tests or new results;
family follow up (eg, a new family member is referred to the clinic and
this triggers a review of the family ﬁles); reclassiﬁcations of VUSs;
reproductive relevance (eg, when children of parents with a genetic
condition reach reproductive age); recruit former patients to partici-
pate in research projects. However, there was no uniform recontacting
system; the cases discussed were the result of diverse personal systems
they had developed, often reliant on their own memory.
I’ve seen thousands of patients in my time here. If there’s a new gene,
I might remember some of them. Sadly we have no efﬁcient database
to recall patients. So when I leave, the memory of those patients is gone
(Genetic consultant 1)
As illustrated, these personal systems were often felt to be inefﬁcient
and unsustainable. For some this is likely to be exacerbated in the
context of expanding services (as more patients are referred to genetic
services, remembering each one becomes less possible). Recontacting
appeared to be bespoke to the speciﬁc patient and/or family. Deciding
Table 1 Participant occupations
Clinical genetics healthcare professionals Genetic consultants 10
Genetic counsellors 5
Trainee doctors in clinical genetics 4
Clinical genetics scientists Scientist 2
Head of laboratory 1
Mainstream healthcare professionals Paediatricians 3
Cardiologists 2
Haematologists 1
Endocrinologists 1
Oncologists 1
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whether or not to recontact, and how to do so, often required a review
of the patient case and clinical history.
I think reviewing the individual cases is important because sometimes it’s
not appropriate to recontact, sometimes that person has passed away and
there’s no more relevance, sometimes you know that the family structure
is such that now would not be a good time… (Genetic counsellor 1)
Some genetic HCPs expressed concern towards the patients
potentially missed due to the current ad hoc recontacting practices:
At the minute it [recontacting] is opportunistic. If I remember the
family very well and I remember that they want to be recontacted or if
it comes across my desk because of an audit, or another project, or
another family member and it’s obvious that they wish to be
recontacted and there’s something to be gained, but there must be
many ﬁles ﬁled away that I know nothing about where patients could
beneﬁt (Genetic consultant 7)
Databases, or the lack thereof, were mentioned frequently. Indeed, a
common theme across all participants was that there was a tension
between the desirability in principle of recontacting, and its practical
feasibility given the constraints in the NHS.
I think it would be good to do it. I think it’s also one of those many
things within the NHS where there is an uncomfortable mismatch
between what we would ideally like to do and what we have the
capacity to do. So in an ideal world, yes we would recontact. [But]
when you have to make a choice between recontacting and serving
other clinical needs we may not (Genetic counsellor 1)
As this participant alluded, HCPs thought recontact important, but
had to make careful judgements about how best to allocate their
limited resources.
Unclear lines of responsibility
Another important perceived barrier to recontacting was the lack of
clarity about roles, including whose responsibility it would be to initiate
any recontact. This was complicated by the increasing use of genetic
testing by mainstream medical specialties. The majority of respondents
considered genetic HCPs their preferred recontact route – given their
ability to communicate complexities of genomic information, and, as the
quotation below suggests, because of existing patient registers.
If we want to do an audit in cardiology I think cardiology can’t even
identify patients with hypertrophic cardiomyopathy, whereas we
can… not perfectly, but we can identify notes and pull them [...].
I think the cardiologists would… they have told me, ‘Why haven’t you
recontacted them?’ (Genetic consultant 7)
Some genetic HCPs, however, challenged this view, arguing that
other specialties more involved in on-going treatment, and the patients
themselves, should share responsibility for recontacting, for example if
their clinical situation changed or the patient was planning a family, was
pregnant, or had a child. According to this view, genetic HCPs’ role is
not to actively recontact, but rather, it is patients’ and other healthcare
professionals’ role to recontact genetic HCPs to ask for updates.
They need to recontact us, recontact doesn’t work one way. I think it
should come from the patients and families. And the doctors who
ofﬁcially are paid to look after their care […] I feel there’s less
responsibility on us to recontact people as on people and other
specialists, doctors, to recontact us to ﬁnd out what’s changed since
(Genetic consultant 1)
There was also lack of clarity between genetic HCPs and clinical
scientists in the laboratory in relation to whose role it should be to
keep up to date with the reclassiﬁcation of variants that trigger
recontact. Some genetic HCPs expected to be updated by the
laboratory about reclassiﬁcations.
I feel that it’s more the responsibility of the laboratory who has done
the testing to actually notify the clinicians that they [VUSs] have been
re-classiﬁed. I’ve had a case recently […] there is a VUS that has been
identiﬁed in the family that is now classiﬁed as pathogenic and for me
to be able to use it I need the laboratory to re-issue the reports and in
this case it’s been me who has come back to the laboratory, but I feel
it’s more their responsibility to notify me (Genetic consultant 3)
Some clinical scientists argued for a two-way responsibility between
the laboratory and HCPs, and highlighted how the laboratory
normally responds to genetic HCPs’ requests.
I can’t possibly be a specialist in every clinical area. I'm a head of a lab
but we provide services for 1800 different disorders. I try to be very
responsive to a clinician asking the question because they know their
patients, they know those disorders, That’s where I see my role and the
lab’s role is to be responsive to that. But then within the laboratory
you also have scientists who’re specialists in certain scientiﬁc areas and
I think they also have a role to bring to the attention of the service, to
me and of the clinical team [that] there is this new development, there
is a new gene. So I think we've got a responsibility, the responsibility is
two-way (Head of laboratory)
Recontacting requires multidisciplinary collaboration
Rather than identifying a speciﬁc specialty as being responsible for
recontacting, others have argued that this responsibility should be
shared among all the medical specialties and laboratory scientists
involved in the diagnosis, treatment and management of patients.
This suggestion was corroborated by the recontacting cases
(both related to the vignettes and HCPs’ own practice) discussed
during the interviews. For example, decisions made by genetic HCPs
about whether and how to recontact often required collaboration with
colleagues, mainstream specialities, and the laboratory. Collaborations
were also mentioned in relation to the review of the accuracy and
clinical signiﬁcance of new genetic information (eg, VUSs). Multi-
disciplinary collaborations were regarded as one of the most effective
ways to reduce misunderstandings about roles and responsibilities
between healthcare professionals in the management of patients.
The multidisciplinary process, it’s the diagnosis, it’s the management, it’s
the information pipelines, it’s the wider family issues, and if you are not
doing that then you are not addressing the problem at the right level.
If you try and fragment it [...] without a doubt things will be missed and
they will be missed simply because there’s pressure on time, there’s
pressure on people, etc… …. I think however it’s done, in this age of
rapidly expanding knowledge, understanding and uncertainty, you’ve got
to have mechanisms that are going to address it (Genetic consultant 4)
Patients should (sometimes) share responsibility
Some respondents argued in favour of the idea that patients should
share responsibility for recontacting by agreeing to contact healthcare
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professionals when an event in their family happens that is relevant (eg, a
new birth), and at regular intervals to ask for updates. This was presented
as being advisable with current limited resources, and in line with the
trend to give patients more autonomy and control over their health.24
I always say to patients that as things change we can’t guarantee
[recontact], so you should recontact us if anything changes in your
family, or if you read anything that concerns you and you want to
know if it’s relevant […] a lot of people are very reactive and not
proactive about their health I absolutely think people should recontact
[…]. I deﬁnitely think there’s a shared responsibility, it’s their health
(Genetic consultant 5)
However, a few healthcare professionals’ pointed out that patients
are diverse (in terms of their needs, education, socio-cultural back-
grounds, and their capacity for autonomy), and so the shared
responsibility model will not always be appropriate:
I think they can share that responsibility, but I think they should have
the right for us to take full responsibility. If they choose not to, and I'm
thinking of many of the children I see with a neurodisability, their
parents may be affected by a similar learning disability, it would be
unreasonable to expect them to take some responsibility for that. So I
think they have to be allowed to give up that responsibility, and for us
to take it (Paediatrician 1)
A consensus about recontact is needed
The majority of respondents found the lack of consensus about the
existence of a duty to recontact, and the potential professional and
legal consequences of (not) recontacting, to be problematic.
You could be sued in either direction if you are going to worry about
those things. I know some people within our team are very conscious of
the legal aspects. If you didn’t give someone that information […] then
there is an implication there. How a court would judge it in terms of
how far does your responsibility go, I don’t know. I think in a way there
may be court cases in the future and I don’t feel that I’m clear on…
well what’s the ground rule, how far are we expected to go, where does
our formal legal responsibility end up? (Genetic counsellor 1)
Some expressed skepticism towards the idea of introducing legisla-
tion or guidelines, arguing that these would stiﬂe clinical practice and
judgment. However, the need to reach a professional consensus about
the existence of a responsibility or duty to recontact was highlighted by
the vast majority of respondents.
I think as a specialty, as a group of health professionals we really need
to have an awful lot of considered debate to say actually what do we
do with all this information? (Genetic counsellor 2)
Reaching this consensus – that is, agreeing and clarifying the role(s)
of clinical genetics and other specialties – was generally seen as a key
pre-requisite to any decision about developing recontacting guidelines
and/or legislations. Another important prerequisite was the clariﬁca-
tion of necessary resources and infrastructures.
I think pragmatically this requires a watertight data automation, any
guideline or best practice... should dictate how the dataset is kept and
monitored. If this is reliant on people recalling, or making an effort, or
personal reading, and therefore thinking, ‘I've read article A, and I'll
therefore go and seek for this...’ that will fail. If it is too ad hoc, it's
better in a way not to have it, and so that people know they have to
keep checking (Paediatrician 1)
Finally, the need to have more information about patients’ expectations
of, and preferences for, recontact, and to address the ‘gap’ between the
expectations of patients’ and healthcare professionals’ was also highlighted.
Do patients believe that if there was something out there we would let
them know? Because if they are relying on that, and it’s not
happening, then that’s quite a worrying gap (Genetic counsellor 1)
DISCUSSION
Overall our ﬁndings support the idea that recontacting is an issue of
increasing concern in a health service engaging with the rapidly
evolving ﬁeld of genomic medicine. Our participants thought it to be a
desirable standard of care, but were uncertain whether effective
guidelines were possible or desirable. The data highlight several issues
that now need urgent consideration in order to decide whether and
how recontacting should be implemented.
Currently, recontacting is ‘opportunistic’, as described by one respon-
dent, and this raises the question of equitable healthcare service provision.
More efﬁcient automated patient databases may mitigate some of the
resource issues, helping healthcare professionals to identify patients who
may beneﬁt from a recontact (or to keep patients up to date if models of
shared responsibility are adopted), and allow for more, and more
consistent recontacting. However the recontacting that does take place
appears to be bespoke to individual patients and families and cognizant of
the sensitivity of communicating new information. Complete automation
would not allow for this bespoke element of recontacting.
Clarifying professional roles and responsibilities for recontacting – for
example, in relation to who (between genetic HCPs and clinical scientists
in the laboratory) should keep up to date with the reclassiﬁcations of
VUSs – is of pressing importance. Because of this lack of clarity, we are
hesitant to adopt the term ‘duty’ and we prefer the term ‘responsibility’
(we noticed that also our respondents tended to use the word
‘responsibility’, rather than ‘duty’). The term ‘duty’ appears to establish
a binding framework of liability which presupposes clarity about who
should perform such a duty. ‘Responsibility’ can instead be used more
broadly to denote the existence of a potential obligation when there is
lack of clarity about who is involved in this obligation. Interestingly, the
term ‘responsibility’ lends itself more easily than ‘duty’ to describe
situations in which patients may also be involved in recontacting.
It makes more sense to say that patients could sometimes share with
HCPs the responsibility for recontacting – as some respondents suggested
(eg, by agreeing to contact HCPs at regular intervals to check for updates)
– rather than share HCPs’ duty to recontact. We are planning to
investigate this important issue of differences between ‘duty’ and
‘responsibility’ further. We are aware that this issue is also linked to the
ambiguity between legal and professional forms of governance – which is
another key concern to healthcare professionals.
Professional debates involving genetic HCPs and other specialties
attempting to reach an agreement about whether a duty or respon-
sibility to recontact exists and whose role it would be to recontact may
offer a suitable opportunity to start addressing some of these key
recontacting issues. We suggest a few questions for consideration to
guide future policy and professional debates about whether and how
recontacting should take place (see Table 2 below).
We recognise that the problem of recontacting does not arise solely in
relation to genetic testing. There have been recent cases of patient recall
for example in relation to PIP (Poly Implant Prothese),25 and to
concerns that a dentist may have transmitted Hepatitis C infection to
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patients.26 Both these examples involved widespread dissemination of
information to the public, setting up helplines, and requiring the patient
to share some responsibility for contacting healthcare professionals.
More evidence, possibly also from other specialties, is needed to inform
any debate about whether and how to implement recontacting systems.2
The interviews we conducted represent only a phase of a broader
ongoing study. We are currently investigating patients’ expectations
regarding responsibilities and mechanisms for recontacting. We also
aim to disseminate our ﬁndings to other stakeholders (including
patient groups, and relevant professional organisations), and we expect
this to lead to a discussion about drafting professional guidance
regarding recontacting in the UK (and possibly other countries), or
working toward a professional framework, as appropriate.
There are some limitations to this study. Although varied, the
sample is limited; other HCPs in the UK may express different views.
Moreover, interviews were undertaken in the UK which has a National
Health Service and a long-established clinical genetics service; the
ﬁndings may not be applicable to the rest of Europe and to other
countries which have different models of healthcare systems, and/or
less established clinical genetics services.
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Table 2 Key recontacting questions
Qualitative questions
What are the differences and implications, if any, between professional, legal, and ethical duties or responsibilities to recontact?
Whose professional role(s) would it be to recontact?
What does holding information mean in terms of responsibility or duty?
Practical questions
In what situations would it be relevant (eg, only when new information has tangible impact on patient management)?
How often, and over what span of time, would genetic services be expected to conduct repeat laboratory analyses or bioinformatic reinterpretations on any samples or results
that included VUSs?
Which methodologies and infrastructures, if any, might be useful in recontacting systems?
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